Trial Profile
A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Basmisanil (Primary) ; Itraconazole
- Indications Down syndrome
- Focus Pharmacokinetics
- Sponsors Roche
- 25 Aug 2016 Status changed from recruiting to completed.
- 15 Jun 2015 New trial record